Scaling up Xpert MTB/RIF technology: The costs of laboratory- vs. clinic-based roll-out in South Africa

Tropical Medicine and International Health

Volumn 17, Issue 9, 2012, Pages 1142-1151

  Schnippel, Kathryn ^a   Meyer Rath, Gesine ^a,b   Long, Lawrence ^a   Macleod, William ^a,b   Sanne, Ian ^a,b   Stevens, Wendy S ^a,c   Rosen, Sydney ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Diagnostics; Economics; Middle income; Scale up; Tuberculosis

Indexed keywords

RIFAMPICIN;

COST-BENEFIT ANALYSIS; DATA PROCESSING; HEALTH CARE; HEALTH EXPENDITURE; HEALTH SERVICES; INSTRUMENTATION; LABORATORY METHOD; MEDICINE; MICROSCOPY; PUBLIC HEALTH; SOCIOECONOMIC STATUS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ARTICLE; CLINICAL LABORATORY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEALTH CARE COST; HOSPITAL; LUNG TUBERCULOSIS; MEDICAL DEVICE; MEDICAL TECHNOLOGY; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SCALE UP; SENSITIVITY ANALYSIS; SOUTH AFRICA;

COSTS AND COST ANALYSIS; DIAGNOSTIC EQUIPMENT; HUMANS; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

SOUTH AFRICA;

EID: 84865552732     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2012.03028.x     Document Type: Article

References (31)

1. Banada PP, Sivasubramani SK, Blakemore R et al. (2010) Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. Journal of Clinical Microbiology 48, 3551-3557.
2. Bistline K, Van Rie A, Page-Shipp L, Basset J & Sanne I (2011) Cost of Xpert MTB/RIF for smear-negative TB suspects at primary care clinic in Johannesburg. International Journal of Tuberculosis and Lung Disease 15, S61. Lille, France.
3. Boehme CC, Nabeta P, Hillemann D et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 363, 1005-1015.
4. Boehme CC, Nicol MP, Nabeta P et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 6736, 1-11.
5. Cepheid (n.d.). GeneXpert System. from http://www.genexpert.com/pdfs/GeneXpert Brochure_0112-04.pdf (accepted 20 May 2011).
6. Chihota VN, Grant AD, Fielding K et al. (2010) Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. International Journal of Tuberculosis and Lung Disease 14, 1024-1031.
7. Dorman S, Manabe Y, Nicol M, Nakiyingi L, Moodley M & Zemanay W et al. (2012). Accuracy of Determine TB-LAM Lateral Flow Test for Diagnosis of TB in HIV+ Adults: interim results from a Multicenter Study. Conference on Retroviruses and Opportunistic Infections, Oral abstract, paper #149aLB. Seattle, USA.
8. Erasmus LK, Coetzee GJ & Stevens WS (2011) Scale up of Xpert MTB/RIF from the national laboratory perspective: issues and challenges. International Journal of Tuberculosis and Lung Disease 15, S61. Lille, France.
9. Health Systems Trust (2010). The District Health Barometer 2008/09. Health Systems Trust. http://www.hst.org.za/publications/district-health-barometer-200809
10. Helb D, Jones M, Story E et al. (2010) Rapid detection of Mycobacterium tuberculosis and Rifampin resistance by use of on-demand, near-patient technology. Journal of Clinical Microbiology 48, 229-237.
11. Lawn SD, Kerkhoff AD & Wood R (2012) Location of Xpert® MTB/RIF in centralized laboratories in South Africa undermines potential impact. International Journal of Tuberculosis and Lung Disease 16, 701-710.
12. Meyer-Rath G, Schnippel K, Long L et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7(5), e36966. doi:10.1371/journal.pone.0036966.
13. Morris K (2010) Xpert TB diagnostic highlights gap in point-of-care pipeline. The Lancet Infectious Diseases 10, 742-743. Elsevier Ltd.
14. National Department of Health (2009). South African National Tuberculosis Guidelines. National Department of Health, Pretoria.
15. Nicol MP, Workman L, Isaacs W et al. (2011) Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. The Lancet Infectious Diseases 11, 819-824. Elsevier Ltd
16. Oanda.com (2011). Oanda average exchange rates. from http://www.oanda.com/currency/average (accepted 28 September 2011).
17. Page-Shipp L, Dansey H, Basset J et al. (2011) Point of care Xpert MTB/RIF for smear-negative TB diagnosis at a primary care clinic in South Africa. International Journal of Tuberculosis and Lung Disease 15, S61. Lille, France.
18. Scott LE, Mccarthy K, Gous N et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Medicine 8, 1-11.
19. Small PM & Pai M (2010) Tuberculosis diagnosis - time for a game change. New England Journal of Medicine 363, 1070-1071.
20. Smart T (2011). GeneXpert to be rolled out as first-line diagnostic for TB in South Africa. HIV & AIDS treatment in practice. from http://www.aidsmap.com/GeneXpert-to-be-rolled-out-as-first-line-diagnostic-for-TB-in-South-Africa/page/1746803/ (accepted 10 November 2011).
21. South African Reserve Bank (2011). Selected historical exchange rates and other interest rates. from http://www.resbank.co.za/Research/Rates/Pages/SelectedHistoricalExchangeAndInterestRates.aspx (accepted 14 November 2011).
22. Sreeramareddy CT, Panduru KV, Menten J & Van den Ende J (2009) Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infectious Diseases 9, 91 doi:10.1186/1471-2334-9-91.
23. Stop TB Department (2006). Planning and budgeting for TB control model. World Health Organization. from http://www.who.int/tb/dots/planning_budgeting_tool/en/ (accepted 28 July 2011).
24. Stop TB Department (2010). Roadmap for Rolling Out Xpert MTB/RIF for Rapid Diagnosis of TB and MDR-TB (pp. 1-12). World Health Organization, Geneva.
25. Theron G, Pooran A, Peter J et al. (2011) Adjunct TB tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? ERJ. doi: 10.1183/09031936.00145511.
26. Trébucq A, Enarson DA, Chiang CY et al. (2011) Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? International Journal of Tuberculosis and Lung Disease 15, 1567-1571.
27. Vadwai V, Boehme CC, Nabeta P, Shetty A, Alland D & Rodrigues C (2011) Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? Journal of Clinical Microbiology, 49 2540-2545.
28. Van Rie A, Page-Shipp L, Scott L, Sanne I & Stevens W (2010) Xpert ® MTB/RIF for point-of- care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Review of Molecular Diagnosis 10, 937-946.
29. Vassall A, van Kampen S, Sohn H et al. (2011) Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Medicine 8, e1001120.
30. World Health Organization (2011a) Global Tuberculosis Control. World Health Organization, Geneva.
31. World Health Organization (2011b) Rapid Implementation of the Xpert MTB/RIF Diagnostic test: Technical and Operational "How-to"; Practical Considerations. World Health (WHO/HTM/TB.). World Health Organization, Geneva.